Shaun Rosebeck

723 total citations
22 papers, 585 citations indexed

About

Shaun Rosebeck is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Shaun Rosebeck has authored 22 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Hematology and 9 papers in Oncology. Recurrent topics in Shaun Rosebeck's work include Multiple Myeloma Research and Treatments (12 papers), Protein Degradation and Inhibitors (7 papers) and NF-κB Signaling Pathways (5 papers). Shaun Rosebeck is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Protein Degradation and Inhibitors (7 papers) and NF-κB Signaling Pathways (5 papers). Shaun Rosebeck collaborates with scholars based in United States, Poland and Canada. Shaun Rosebeck's co-authors include Douglas W. Leaman, Peter C. Lucas, Linda M. McAllister‐Lucas, Aasia Rehman, Jagoda Jasielec, Mathijs Baens, Ingrid J. Apel, Alex Appert, Andrzej Jakubowiak and Xavier Sagaert and has published in prestigious journals such as Science, Journal of Clinical Oncology and Blood.

In The Last Decade

Shaun Rosebeck

22 papers receiving 580 citations

Peers

Countries citing papers authored by Shaun Rosebeck

Since Specialization

Citations

This map shows the geographic impact of Shaun Rosebeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shaun Rosebeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shaun Rosebeck more than expected).

Fields of papers citing papers by Shaun Rosebeck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shaun Rosebeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shaun Rosebeck. The network helps show where Shaun Rosebeck may publish in the future.

Co-authorship network of co-authors of Shaun Rosebeck

This figure shows the co-authorship network connecting the top 25 collaborators of Shaun Rosebeck. A scholar is included among the top collaborators of Shaun Rosebeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shaun Rosebeck. Shaun Rosebeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Potent anti‐myeloma activity of the TOPK inhibitor OTS514 in pre‐clinical models 2019 ·Cancer Medicine ·Andrew Stefka, David C. Johnson, Shaun Rosebeck, (unknown), Yusuke Nakamura, Andrzej Jakubowiak	13
2	Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma 2019 ·British Journal of Haematology ·Andrzej Jakubowiak, Jagoda Jasielec, Cara A. Rosenbaum, Craig E. Cole, Ajai Chari, Joseph Mıkhael, Jennifer Nam, (unknown), (unknown), (unknown), (unknown), Shaun Rosebeck, Todd M. Zimmerman, (unknown), (unknown), Theodore Karrison, Jeffrey A. Zonder	55
3	API2-MALT1 oncoprotein promotes lymphomagenesisviaunique program of substrate ubiquitination and proteolysis 2016 ·World Journal of Biological Chemistry ·Shaun Rosebeck	9
4	Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells 2016 ·Blood Cancer Journal ·Andrew Stefka, Jin‐hong Park, Yo Matsuo, Sophie H. Chung, Yusuke Nakamura, Andrzej Jakubowiak, Shaun Rosebeck	16
5	Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) 2016 ·Blood ·Todd M. Zimmerman, Noopur Raje, Ravi Vij, Donna Reece, Jesús G. Berdeja, (unknown), Kathryn McDonnell, Cara A. Rosenbaum, Jagoda Jasielec, Paul G. Richardson, Sandeep Gurbuxani, Jennifer Nam, (unknown), (unknown), Shaun Rosebeck, Andrew Stefka, Dominik Dytfeld, Kent A. Griffith, Andrzej Jakubowiak	41
6	Carfilzomib (CFZ, Kyprolis®), Lenalidomide (LEN, Revlimid®), and Dexamethasone (DEX) (KRd) Combined with Autologous Stem Cell Transplant (ASCT) Shows Improved Efficacy Compared with Krd without ASCT in Newly Diagnosed Multiple Myeloma (NDMM) 2016 ·Biology of Blood and Marrow Transplantation ·Todd M. Zimmerman, Kent A. Griffith, Jagoda Jasielec, Cara A. Rosenbaum, Jesús G. Berdeja, Ravi Vij, Noopur Raje, Donna Reece, David H. Vesole, Sundar Jagannath, Mark Kaminski, Craig E. Cole, Jennifer Nam, (unknown), Shaun Rosebeck, Sandeep Gurbuxani, Dominik Dytfeld, Andrzej Jakubowiak	1
7	Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor 2015 ·Molecular Cancer Therapeutics ·Shaun Rosebeck, (unknown), Malathi Kandarpa, Anoop Mayampurath, Samuel L. Volchenboum, Jagoda Jasielec, Dominik Dytfeld, (unknown), (unknown), Dilara McCauley, Sharon Shacham, Michael Kauffman, Andrzej Jakubowiak	40
8	Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib‐based treatment regimens 2015 ·British Journal of Haematology ·Dominik Dytfeld, Shaun Rosebeck, Malathi Kandarpa, Anoop Mayampurath, Dattatreya Mellacheruvu, (unknown), Lambert Ngoka, Jagoda Jasielec, Paul G. Richardson, Samuel L. Volchenboum, Alexey I. Nesvizhskii, Arun Sreekumar, Andrzej Jakubowiak	16
9	Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). 2015 ·Journal of Clinical Oncology ·Todd M. Zimmerman, Kent A. Griffith, Jagoda Jasielec, Cara A. Rosenbaum, Kathryn McDonnell, (unknown), Jesús G. Berdeja, Noopur Raje, Donna Reece, Ravi Vij, (unknown), Shaun Rosebeck, Sandeep Gurbuxani, Malek Faham, Katherine A. Kong, Joan Levy, Andrzej Jakubowiak	10
10	Carfilzomib (CFZ, Kyprolis®), lenalidomide (LEN, Revlimid®), and dexamethasone (DEX) (KRd) combined with autologous stem cell transplant (ASCT) shows improved efficacy compared with KRd without ASCT in newly diagnosed multiple myeloma (NDMM) 2015 ·Clinical Lymphoma Myeloma & Leukemia ·Andrzej Jakubowiak, Kent A. Griffith, Jagoda Jasielec, Cara A. Rosenbaum, Jesús G. Berdeja, Ravi Vij, Noopur Raje, Donna Reece, Shaun Rosebeck, Sandeep Gurbuxani, Dominik Dytfeld, Todd M. Zimmerman	2
11	Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM) 2015 ·Blood ·Andrzej Jakubowiak, Jagoda Jasielec, Cara A. Rosenbaum, Jeffrey A. Zonder, Craig E. Cole, Ajai Chari, Jennifer Nam, (unknown), Kathryn McDonnell, (unknown), Shaun Rosebeck, Tami Rashal, Hagop Youssoufian, Sarah Henry, Sharon Shacham, Michael Kauffman, Todd M. Zimmerman, Theodore Karrison	6
12	Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd) 2014 ·Blood ·Jagoda Jasielec, Dominik Dytfeld, Kent A. Griffith, Kathryn McDonnell, Daniel Lebovic, Malathi Kandarpa, Tara Anderson, M. Mietzel, Malek Faham, (unknown), Joan Levy, (unknown), Shaun Rosebeck, Mark Kaminski, Andrzej Jakubowiak	4
13	Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) 2014 ·Blood ·M. van Vliet, Jagoda Jasielec, Dominik Dytfeld, Ravi Vij, (unknown), (unknown), (unknown), (unknown), Shaun Rosebeck, Malathi Kandarpa, Kathryn McDonnell, Kent A. Griffith, Erik H. van Beers, Andrzej Jakubowiak	7
14	The API2–MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling 2013 ·Oncogene ·Shaun Rosebeck, Aasia Rehman, Ingrid J. Apel, Dawn Kohrt, Alex Appert, Michael A. O’Donnell, Adrian T. Ting, MQ Du, Mathijs Baens, Peter C. Lucas, Linda M. McAllister‐Lucas	25
15	Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM) 2013 ·Blood ·Jagoda Jasielec, Dominik Dytfeld, Kent A. Griffith, Kathryn McDonnell, Daniel Lebovic, Malathi Kandarpa, David H. Vesole, Sundar Jagannath, M. Mietzel, Ravi Vij, Malek Faham, (unknown), Erik H. van Beers, Martin H. van Vliet, Joan Levy, (unknown), Shaun Rosebeck, Mark Kaminski, Andrzej Jakubowiak	3
16	Effects Of Inhibition Of XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330), Alone and In Combination With Carfilzomib (CFZ), On Apoptosis and Autophagy In Multiple Myeloma (MM) 2013 ·Blood ·Shaun Rosebeck, Malathi Kandarpa, (unknown), Jagoda Jasielec, Dominik Dytfeld, (unknown), (unknown), Dilara McCauley, Sharon Shacham, Michael Kauffman, Andrzej Jakubowiak	5
17	Involvement of Noxa in mediating cellular ER stress responses to lytic virus infection 2011 ·Virology ·Shaun Rosebeck, Kuladeep Sudini, (unknown), Douglas W. Leaman	20
18	From MALT lymphoma to the CBM signalosome 2011 ·Cell Cycle ·Shaun Rosebeck, Aasia Rehman, Peter C. Lucas, Linda M. McAllister‐Lucas	68
19	Cleavage of NIK by the API2-MALT1 Fusion Oncoprotein Leads to Noncanonical NF-κB Activation 2011 ·Science ·Shaun Rosebeck, Lisa Madden, Xiaohong Jin, Shufang Gu, Ingrid J. Apel, Alex Appert, Rifat Hamoudi, Heidi Noels, Xavier Sagaert, Peter Van Loo, Mathijs Baens, Ming‐Qing Du, Peter C. Lucas, Linda M. McAllister‐Lucas	120
20	Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a 2008 ·APOPTOSIS ·Shaun Rosebeck, Douglas W. Leaman	95

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact